摘要
泛免疫炎症指数(PIV)是一种基于全血细胞计数的综合性免疫炎症生物标志物,已被证实能够预测不同肿瘤类型的治疗反应和生存结局。然而,PIV在不同肿瘤治疗策略中的预测价值存在差异。本研究旨在系统综述PIV预测免疫治疗、放射治疗、靶向治疗、内分泌治疗、手术治疗以及新辅助治疗等不同肿瘤治疗方式的生存效果指标和肿瘤预后的最新进展,分析其存在的挑战和问题,展望未来发展方向和应用前景。
Pan-immune inflammation value(PIV)is a comprehensive immune inflammatory biomarker based on complete blood cell counts,which has been proven to predict treatment response and survival outcomes for different types of tumors.However,the predictive value of the PIV varies in different strategies for tumor treatment.This paper aims to systematically review the latest progress of PIV in predicting survival outcomes and tumor prognosis for immunotherapy,radiotherapy,targeted therapy,endocrine therapy,surgical treatment and neoadjuvant therapy,and analyze its existing challenges and issues,as well as look forward to its future development direction and application prospects.
作者
李添翼
任粤
宋震亚
江美南
李梦扬
陈勇
殷旭东
LI Tianyi;REN Yue;SONG Zhenya;JIANG Meinan;LI Mengyang;CHEN Yong;YIN Xudong(Department of Oncology,Affiliated Hospital of Yangzhou University,Yangzhou,Jiangsu,225000)
出处
《实用临床医药杂志》
CAS
2024年第5期139-143,共5页
Journal of Clinical Medicine in Practice
基金
江苏省自然科学基金资助项目(BK20191218)
江苏省产学研合作项目(BY20221106)。
关键词
肿瘤
泛免疫炎症指数
预测
预后
疗效
生物标志物
tumors
pan-immune inflammation value
prediction
prognosis
efficacy
biomarkers
